Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100090ApriorityCriticalpatent/CU20100090A7/en
Publication of CU20100090A7publicationCriticalpatent/CU20100090A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
La invención proporciona formulaciones farmacéuticas de polvo seco que comprenden un derivado del ácido ascórbico que presenta un comportamiento inhalatorio bueno e inhaladores de polvo seco que las contienen.The invention provides dry powder pharmaceutical formulations comprising a derivative of ascorbic acid that exhibits good inhalation behavior and dry powder inhalers containing them.
CU20100090A2010-05-072010-05-07
DRY POWDER FORMULATIONS THAT INCLUDE DERIVATIVES OF ASCORBIC ACID
CU20100090A7
(en)
DERIVATIVES OF ESTRA 1,3,5 (10), 16 TETRAENE 3 SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES